SCHEMBL4989433

SCHEMBL4989433

COc1cc(CC2=NCCN2)c(C)cc1NS(C)(=O)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 11/20 0.44
ADRA1D P25100 9/20 0.44
ADRA1B P35368 9/20 0.44
ADRA2A P08913 8/20 0.44
HTR1B P28222 7/20 0.44
HTR1D P28221 7/20 0.44
ADRA2C P18825 7/20 0.44
ADRA2B P18089 3/20 0.44
HTR1A P08908 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP2D6 P10635 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
TSHR P16473 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994047 0.91 ADRA1A (0.44) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4989442 0.88 ADRA1A (0.42) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4994677 0.88 ADRA1A (0.47) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4989505 0.84 ADRA1A (0.47) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4986567 0.81 ADRA1A (0.47) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4989586 0.81 ADRA1A (0.42) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4994698 0.81 HTR1B (0.51) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL5200788 0.81 HTR1B (0.51) ADRA1AADRA1DADRA1BADRA2AHTR1B
SCHEMBL4993343 0.80 HTR1B (0.44) ADRA1AADRA1DADRA1BADRA2AHTR1B
Hydrochloric Acid SCHEMBL5201882 0.80 HTR1B (0.50) ADRA1AADRA1DADRA1BADRA2AHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756395-B2 CYCLIZATION OF N-(4-CYANOMETHYLPHENYL)METHANESULFONAMIDES WITH ETHYLENEDIAMINE TO FORM N-(4-IMIDAZOL-2-YLMETHYL)-PHENYL) -METHANESULFONAMIDES; INCONTINENCE, SEXUAL DYSFUNCTION, NASAL CONGESTION, AND CNS DISORDERS; ALPHA 1 ADRENERGIC AGONISTS ROCHE PALO ALTO LLC 2004-06-29 US claimed
US-7407980-B2 Imidazolinylmethyl aralkylsulfonamides ROCHE PALO ALTO LLC (US) 2008-08-05 US disclosed
US-7407980-B2 Imidazolinylmethyl aralkylsulfonamides ROCHE PALO ALTO LLC (US) 2008-08-05 US disclosed
US-7407980-B2 Imidazolinylmethyl aralkylsulfonamides ROCHE PALO ALTO LLC (US) 2008-08-05 US disclosed